http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Keeping the Family : Coping with the Challenges of the 21st Century
Celso C, Atty,Ph. D., Talaba 선문대학교 통일사상연구원 1999 통일사상 연구논총 Vol.6 No.-
All these questions address scientific development and breakthroughs which have underscored mans seemingly unlimited potential to discover and create. For all these fascinating possibilities, there remains the social institution, which has to be examined and strengthened if we are to sustain and enjoy the fruits of scientific progress.
A New Voltage(Current)-Controlled Current-Feedback Operational-Amplifier Based Mulivibrator
Muhammad Taher Abuelma’atti,Zainualbideen Jamal Khalifa 대한전자공학회 2015 ITC-CSCC :International Technical Conference on Ci Vol.2015 No.6
In this paper a simple multivibrator circuit is proposed. The circuit uses two current-feedback operational amplifier. The duty cycle of the output rectangular wave can be controlled by adjusting a control voltage. The duty cycle can also be controlled by adjusting a control current instead of the control voltage.
Prediction of Gain Expansion and Intermodulation Performance of Nonlinear Amplifiers
Muhammad Taher Abuelma'atti 한국전자통신연구원 2007 ETRI Journal Vol.29 No.1
A mathematical model for the input-output characteristic of an amplifier exhibiting gain expansion and weak and strong nonlinearities is presented. The model, basically a Fourier-series function, can yield closedform series expressions for the amplitudes of the output components resulting from multisinusoidal input signals to the amplifier. The special case of an equal-amplitude two-tone input signal is considered in detail. The results show that unless the input signal can drive the amplifier into its nonlinear region, no gain expansion or minimum intermodulation performance can be achieved. For sufficiently large input amplitudes that can drive the amplifier into its nonlinear region, gain expansion and minimum intermodulation performance can be achieved. The input amplitudes at which these phenomena are observed are strongly dependent on the amplifier characteristics.
Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
Ashraf Mahmoud El-Enbaby,Nadia Ahmed Abd El Moneim,Gehan Abd El atti Khedr,Yasmine Mohamed Nagy Elwany 대한종양외과학회 2018 Korean Journal of Clinical Oncology Vol.14 No.2
Purpose: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epider�mal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, and overall survival. Methods: The study included 60 non-metastatic HER2-positive breast cancer patients. All study patients underwent surgery, received adju�vant chemotherapy, radiotherapy and hormonal therapy if indicated. Thirty patients were randomized in each group. Group I patients received adjuvant trastuzumab for 12 months, while group II patients received adjuvant trastuzumab for 9 months. Patients were assessed by clinical examination and Echocardiography during treatment. Results: After median follow-up of 12 months, 90% of the patients in group I were disease free and 83.3% of patients in group II were dis�ease free (P=0.402). All studied population in both groups I and II were alive at the end of the 1-year follow-up period after the completion of adjuvant trastuzumab treatment thus overall survival is 100%. Conclusion: Trastuzumab is tolerable and its side effects are reversible. Nine months of adjuvant trastuzumab treatment is more cost effec�tive than the standard 12 months.
Fabrizio Chiusolo,Teresa Capriati,Ilaria Erba,Roberto Bianchi,Marta Luisa Ciofi degli Atti,Sergio Picardo,Antonella Diamanti 대한소아소화기영양학회 2020 Pediatric gastroenterology, hepatology & nutrition Vol.23 No.6
Purpose: Malnutrition is a common feature in critically ill children. Enteral nutrition (EN) is the main strategy to nutritionally support critical ill children, but its use can be hindered by the development of intolerance. The study aimed to assess the effectiveness and safety of amoxicillin/clavulanate (A/C) to treat EN intolerance. Methods: We retrospectively evaluated patients admitted to the pediatric intensive care unit from October 2018 to October 2019. We conducted a case-control study: in the first 6 months (October 2018-April 2019) we implemented the nutritional protocol of our Institution with no drug, whereas in the second half (May 2019-October 2019) we employed A/C for 1 week at a dose of 10 mg/kg twice daily. Results: Twelve cases were compared with 12 controls. At the final evaluation, enteral intake was significantly higher than that at baseline in the cases (from 2.1±3.7 to 66.1±27.4% of requirement, p=0.0001 by Wilcoxon matched-pairs signed rank test) but not in the controls (from 0.2±0.8 to 6.0±14.1% of the requirement, p=NS). Final gastric residual volume at the end of the observation was significantly lower in the cases than in the controls (p=0.0398). The drug was well tolerated as shown by the similar safety outcomes in both cases and controls. Conclusion: Malnutrition exposes critically ill children to several complications that affect the severity of disease course, length of stay, and mortality; all may be prevented by early EN. The development of intolerance to EN could be addressed with the use of A/C. Future prospective clinical trials are needed to confirm these conclusions.